Ann: FY21 Results Presentation, page-2

I like this chart.

Shows MDR is turning around Adheris revenue's back to its former highs.

FY18 - US$43.8M
FY21 - US$35.3M
Lots more revenue to go after.

FY18 - 123 programs
FY21 - 82 programs
Lots more programs to go after.

MDR is also achieving higher revenues per program.

I listened to the Investor Presentation.

A good, cheeky question was asked - with 75% of revenues coming from the US, why is MDR listed on the ASX and not a US exchange?

Guidance for H1FY22 is given at $30M+.

Hopefully H2FY22 they can provide guidance of $35M.